Advertisement
The American Journal of Medicine
Advanced searchSave search
Review|Articles in Press

New Drugs Approved in 2022

Published:March 06, 2023DOI:https://doi.org/10.1016/j.amjmed.2023.02.019
New Drugs Approved in 2022
Previous ArticleThe management of sarcoidosis in the 2020’s by the primary care physician
Next ArticleNot so fast on virtual interviewing

      Abstract

      In 2022, the US Food and Drug Administration (FDA) approved 37 novel drugs. Twenty-four of the 37 (65%) novel drug approvals were reviewed and approved through an expedited review pathway and 20 of the 37 (54%) were approved for treatment of a rare disease. This review includes a summary of the novel drugs approved by the FDA in 2022.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      1. US Food and Drug Administration (FDA). Novel drug approvals for 2022. Available at:https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2022. Accessed January 16, 2023.

        View in Article

      2. Center for Drug Evaluation and Research, US Food and Drug Administration (FDA). Advancing health through innovation: new drug therapy approvals 2022. Available at: https://www.fda.gov/media/164429/download. Accessed January 16, 2023.

        View in Article

      3. Mykardia Inc. CAMZYOS package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214998s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      4. Pfizer Labs. CIBINQO package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213871s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      5. Revance Therapeutics Inc. DAXXIFY package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761127s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      6. MediWound LTD. NEXOBRID package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761192s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      7. Bristol-Myers Squibb Inc. SOTYKTU package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214958s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      8. Boehringer Ingelheim Pharmaceuticals Inc. SPEVIGO package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761244s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      9. Dermavant Sciences Inc. VTAMA package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      10. Eli Lilly and Company. MOUNJARO package insert. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      11. Provention Bio, Inc. TZIELD package insert. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2022/761183s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      12. Alnylam Pharmaceuticals, Inc. AMVUTTRA package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215515s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      13. Agios Pharmaceuticals, Inc. PYRUKYND package insert. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216196s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      14. Genzyme Corporation. XENPOZYME package insert. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761261s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      15. Marinus Pharmaceuticals, Inc. ZTALMY package insert. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215904s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      16. Bioverative USA Inc. ENJAYMO package insert. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761164s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      17. Genentech, Inc. LUNSUMIO package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761263s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      18. Forma Therapeutics, Inc. REZLIDHIA package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      19. Janssen Pharmaceutical Companies. TECVAYLI package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761291s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      20. CTI Biopharma Corp. VONJO package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208712s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      21. Spectrum Pharmaceuticals, Inc. ROLVEDON package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761148Orig1s000Corrected_lbl.pdf. Accessed March 16, 2023.

        View in Article

      22. Gilead Sciences, Inc. SUNLENCA package insert. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215973s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      23. Mycovia Pharmaceuticals, Inc. VIVJOA package insert. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215888s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      24. Phathom Pharmaceuticals, Inc. VOQUEZNA package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215152s000,215153s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      25. TG Therapeutics, Inc. BRIUMVI package insert. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761238s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      26. Guerbet LLC. ELUCIREM package insert. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216986s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      27. Amylyx Pharmaceuticals, Inc. RELYVRIO package insert. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216660s000lbledt.pdf. Accessed March 16, 2023.

        View in Article

      28. ImmunoGen, Inc. ELAHERE package insert. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2022/761310s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      29. AstraZeneca Pharmaceuticals, LP. IMJUDO package insert. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761289s001lbl.pdf. Accessed March 16, 2023.

        View in Article

      30. Immunocore Limited. KIMMTRAK package insert. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761228s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      31. Mirati Therapeutics, Inc. KRAZATI package insert. Available at:www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      32. Taiho Pharmaceutical Co., Ltd.. LYTGOBI package insert. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801Orig1s000lbledt.pdf. Accessed March 16, 2023.

        View in Article

      33. Bristol-Myers Squibb Company. OPDUALAG package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761234s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      34. Novaratis AG. PLUVICTO package insert. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      35. Santen Incorporated. Omlonti package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215092s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      36. Genentech, Inc. VABYSMO package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761235s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      37. Idorsia Pharmaceuticals US Inc. QUVIVIQ package insert. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214985s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      38. Polarean, Inc. XENOVIEW package insert. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2022/214375s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      39. Mallinckrodt Pharmaceuticals. TERLIVAZ package insert. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022231s000lbl.pdf. Accessed March 16, 2023.

        View in Article

      40. US Food and Drug Administration (FDA). FDA drug competition action plan. Available at:https://www.fda.gov/drugs/guidance-compliance-regulatory-information/fda-drug-competition-action-plan. Accessed January 16, 2023.

        View in Article

      41. Conrad R, Lutter R; US Food and Drug Administration (FDA). Generic competition and drug prices: new evidence linking greater generic competition and lower generic drug prices. Available at: https://www.fda.gov/media/133509/download. Accessed January 16, 2023.

        View in Article

      42. Conrad R, Davis K, Glos L, Liu W; US Food and Drug Administration (FDA). Estimating cost savings from new generic drug approvals in 2018, 2019, and 2020. Available at: https://www.fda.gov/media/161540/download. Accessed January 16, 2023.

        View in Article

      Article info

      Publication history

      Published online: March 06, 2023
      Accepted: February 7, 2023
      Received: February 6, 2023

      Publication stage

      In Press Journal Pre-Proof

      Footnotes

      Funding: None.

      Conflicts of Interest: None.

      Authorship: All authors had access to the data and contributed to the preparation of this manuscript.

      Identification

      DOI: https://doi.org/10.1016/j.amjmed.2023.02.019

      Copyright

      © 2023 Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX